Loading clinical trials...

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT01396070

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically mycosis fungoides (MF)...

Lead sponsor: Youn Kim•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGEARLY Phase 1

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

NCT07312630 · Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult

RECRUITING

TreAtments and outComes in paTients With prImary CutAneous Lymphoma

NCT05518851 · Primary Cutaneous Lymphoma

Active Not RecruitingPhase 2

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

NCT01352520 · CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, and more

Active Not RecruitingPhase 1

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

NCT03602157 · Lymphoma, Immune System Diseases, and more

Active Not RecruitingPhase 2

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

NCT02790515 · Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 5, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment36

Start dateMay 2011

Last updatedApr 5, 2017

Condition

Non-Hodgkin Lymphoma (NHL)Cutaneous Lymphoma Cutaneous T-cell Lymphoma (CTCL)Mycosis Fungoides Sezary Syndrome

Locations shown

Stanford University School of Medicine

Stanford, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 5, 2017Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions